This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Defensive lineman Desmond Watson shed 26 pounds in less than a month, but if selected in the NFL draft would still be heaviest player ever picked.

Studies in neuroscience with applications to humans offer clues about what makes us start eating, and when we stop.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Fridays weight loss is a telehealth provider that offers access to popular GLP-1 medications, including compounded versions ...

GLP-1 medicines can be helpful tools for the treatment of obesity and for other important health goals, but they’re not for ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...